WO2002102770A1 - Nouveau compose aliphatique, technique de synthese et technique d'utilisation - Google Patents
Nouveau compose aliphatique, technique de synthese et technique d'utilisation Download PDFInfo
- Publication number
- WO2002102770A1 WO2002102770A1 PCT/JP2002/006067 JP0206067W WO02102770A1 WO 2002102770 A1 WO2002102770 A1 WO 2002102770A1 JP 0206067 W JP0206067 W JP 0206067W WO 02102770 A1 WO02102770 A1 WO 02102770A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- integer
- pharmaceutically acceptable
- acceptable salt
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Definitions
- the present invention relates to novel aliphatic compounds, medicaments containing them, suppression of platelet aggregation, suppression of inflammation and their use in the prevention or treatment of cardiovascular diseases.
- the platelets When the blood platelets come into contact with the subendothelial tissue after the vascular cells have been damaged and detached, the platelets in the blood cause adhesion and agglutination reactions, which lead to the formation of blood clots and thrombosis and other vascular disorders. cause.
- platelet functions such as adhesion and aggregation functions
- stimulants such as collagen, arachidonic acid, ADP, thrombin, serotonin, or epinephrine stimulate each receptor on the platelet membrane
- stimulation is transmitted. It is thought that the glycoprotein complex GPI lb-IIIa on the membrane can bind to fibrinogen in the blood via the system, and platelets are cross-linked and aggregated.
- antiplatelet drugs are those that act on stimulatory receptors and those that act on the stimulus transduction system (PG metabolism inhibitors, involved in cAMP metabolism ) And GPIIb-IIIa.
- GPIIb-IIIa receptor antagonists block the end point of the above-mentioned platelet response, thus inhibiting any platelet response regardless of the cause of the platelet response.
- conventional GPIIb / IIIa receptor antagonists The efficacy of a single dose is about 0.1 to 1 mg I kg by intravenous administration, which is not sufficiently strong.
- the present inventors have conducted extensive research and as a result, have newly discovered a compound represented by the following general formula I or a stereoisomer thereof, and have newly discovered this compound (hereinafter, including its stereoisomer, including its stereoisomer).
- the compound was found to exhibit a much stronger inhibitory effect on platelet aggregation than conventional GPIIb / IIIa receptor antagonists, and also to exhibit an anti-inflammatory effect.
- This effort is based on this finding, and its purpose is to provide a novel aliphatic compound, a method for producing the same, and a medicament.
- the present invention provides a compound of the general formula I
- A is CH 3 C n H ( 2n- 1 2m )-(n is any integer between 4 and 22; m is an unsaturated number; 0 to 7 Which is any integer between).
- R is an alkyl group having 1 to 10 carbon atoms which may be linear or branched, and R A is hydrogen. Or an alkyl group having 1 to 10 carbon atoms which may be linear or branched) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
- FIG. 1 is a graph showing the effect of the compounds of the present invention (compounds:! To 9) on platelet aggregation in a dose-dependent manner at i n V i t ro, similarly to indomethacin.
- FIG. 2 is a graph showing the change over time of the action of the compound of the present invention (Compound 2) to suppress platelet aggregation in eXVivo.
- FIG. 3 is a graph showing the effect of the compound of the present invention (Compound 2) on platelet aggregation in a dose-dependent manner in eXvivo.
- FIG. 4 is a graph showing the effect of the compound of the present invention (compound 5) on platelet aggregation in eXVivo.
- FIG. 5 is a graph showing the effect of the compound of the present invention (Compound 2) on inhibiting platelet aggregation by oral absorption.
- FIG. 6 is a graph showing that in the case of administration of the compound of the present invention after induction of leg necrosis, the death score is improved in a peripheral circulation disorder model in a dose-dependent manner.
- FIG. 7 is a graph showing that in the case of administration of the compound of the present invention before the induction of leg necrosis, the necrosis score is improved in a peripheral circulation disorder model in a dose-dependent manner.
- Figure 8 shows that administration of an O / W emulsion of the compound of the present invention before leg necrosis induction improves the necrosis score in a peripheral circulation disorder model in a dose-dependent manner. It is rough.
- FIG. 9 is a graph showing that the compounds of the present invention (Compounds 1 and 2) exert an inhibitory effect on the migration of neutrophils to vascular endothelial cells.
- FIG. 10 is a graph showing that the compound of the present invention (Compound 2) improves cerebral infarction in a middle cerebral artery occlusion model.
- FIG. 11 is a graph showing that the O / W emulsion preparation of the compound of the present invention suppresses intimal hyperplasia in a dose-dependent manner in a post-PTCA restenosis model.
- FIG. 12 is a graph showing the effect of the compound of the present invention (Compound 2) on inhibiting the proliferation of vascular smooth muscle cells in a concentration-dependent manner. '' Best mode for carrying out the invention
- an alkyl group having 1 to 10 carbon atoms which may be linear or branched include methyl, ethyl, monopropynole, isopropyl, —butyl, isobutyl, t ⁇ r ⁇ -butyl, sec-butyl, 1-pentynole, tert-amyl, 3-methylbutyl, neopentyl, —hexynole, n-heptyl, —octynole, —nonyl, 3-decyl And an alkyl group such as a group.
- Optionally substituted CH 3 be C n H (2 n _ 2ra ) - " means a CH 3 C n H (2 n _ 2m) one having an optional substituent.
- Examples of the optional substituent include a hydroxyl group, a halogen atom, an alkyl group having 1 to 10 carbon atoms which may be linear or branched, a cycloalkyl group having 3 to 7 carbon atoms, and an aryl group.
- cycloalkyl group having 3 to 7 carbon atoms include a cyclopropyl group, a butyl group, a pentyl group, a hexyl group, a hexyl group and a heptyl group.
- aryl group examples include a phenyl group.
- alkyl group having 1 to 10 carbon atoms which may be linear or branched are as described above.
- Preferred embodiments of the compounds of the general formula I of the present invention include the following.
- A—CONH— (CH 2 ) one preferred substitution position is carbon adjacent to N—R.
- R is preferably methyl, ethyl, propyl, isopropyl and dibutyl, more preferably methyl and diethyl, and most preferably a methyl group.
- R A is preferably hydrogen, but when R A is an alkyl group, it preferably has 1 to 6 carbon atoms, and more preferably has 1 to 4 carbon atoms.
- a substitution position in the ring of R A is preferably a position that is not adjacent to N—R.
- 1 is preferably any integer between 0 and 3.
- n is preferably any integer between 6 and 22, and more preferably any integer between 14 and 22.
- m is preferably any integer between 1 and 7, and more preferably any integer between 2 and 6.
- the optional substituent of A preferably does not affect the solubility of the compound of formula I.
- the substituent is alkyl, it is preferably one having a low molecular weight, for example, an alkyl group having 1 to 4 carbon atoms, and more preferably a methyl group.
- Preferred substitution positions are those that are not adjacent to the amide bond, for example, positions 3 to 23, more preferably positions 3 to 20.
- a preferred example of A having a substituent is, in the case of a derivative having a substituent 0H, the hydroxylation of docosahexaenoic acid (DHA) or the hydroxylation of eicosapentaenoic acid (EPA). Although it may be derived from a conductor, it is more preferably derived from a hydroxylated derivative of docosahexaenoic acid (DHA).
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- the configuration of the hydroxylated derivative may be in the (R) configuration or the (S) configuration.
- DHA docosahexanoic acid
- EPA eicosapentaenoic acid
- 12-OH-EPA eicosapentaenoic acid
- the preferred compounds of the present invention include the following compounds, their optical isomers or their optical isomers. And pharmaceutically acceptable salts.
- the stereoisomer in the present invention is meant to include any optical isomer of (R), (S) and racemate, and any geometric isomer of cis, trans and mixtures thereof. In geometric isomerism, cis is preferred.
- the pharmaceutically acceptable salts in the present invention include, for example, salts with mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methanesulfone Acids and salts with organic acids such as benzenesulfonic acid.
- mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid
- acetic acid such as acetic acid, oxalic acid
- lactic acid tartaric acid, fumaric acid, maleic acid, methanesulfone Acids and salts with organic acids such as benzenesulfonic acid.
- salts such as hydrochloride, citrate and maleate are preferred.
- the compound of the present invention can selectively inhibit platelet aggregation, particularly platelet aggregation induced by collagen. As shown in the results of the experiments described below, the compound of the present invention exhibited an inhibitory effect on platelet aggregation in ex vivo, which was lower than that of a conventional GPIIb / IIIa receptor antagonist. Stronger than the ones.
- the compound of the present invention can suppress inflammation caused by inflammatory site such as TN Fa and PDGF.
- the compound of the present invention can be used for preventing or treating cardiovascular diseases.
- a circulatory disease refers to a disease in which the circulation state of blood and lymph is impaired, causing damage to tissues and cells, for various reasons such as platelet aggregation, inflammatory cytokines such as TNFa and PDGF. Includes everything that occurs. Examples include thrombotic, atherosclerotic or hyperlipidemic diseases.
- thrombotic disease refers to a state in which blood vessels are obstructed by thrombus, and is classified into arterial thrombosis and venous thrombosis.
- Arterial thrombosis is mainly caused by atherosclerosis, coronary thrombus causes myocardial infarction, and cerebral artery thrombus causes cerebral infarction.
- Venous thrombosis includes superficial and deep vein thrombosis, for example, deep vein thrombosis.
- Thrombotic diseases include, for example, unstable angina, myocardial infarction, infarction associated with a prosthetic valve, transplant vascular occlusion after coronary artery bypass surgery, transient ischemic attack, cerebral infarction, atherosclerotic peripheral artery Obstruction, erythromelalgia (thrombocythemia), thrombosis of hemodialysis shunt, exertional angina, reocclusion after PTCA, occlusion after vascular reconstruction surgery, etc. (“Thrombosis treatment” Medical Review, 1 The first edition was published on June 20, 1996, written by Yasuo Ikeda).
- arteriosclerotic disease refers to a state in which the wall thickness of the artery is thickened and the elasticity is lost.
- Arteriosclerosis includes three types: atherosclerosis, Monkeberg-type arteriosclerosis, and small arteriosclerosis.
- Arteriosclerotic diseases include cerebral infarction and cerebral hemorrhage in the cerebral artery, ischemic heart disease such as myocardial infarction and angina in the coronary artery, aortic aneurysm, aortic aneurysm in the aorta, and renal sclerosis in the renal artery. This can lead to renal failure and peripheral artery sclerosis.
- the hyperlipidemic disease refers to a condition in which serum cholesterol and / or triglyceride levels are increased, and examples thereof include hypercholesterolemia and hyperneutral lipidosis.
- Each compound of the present invention can be administered orally or parenterally (injection, external preparation, suppository, etc.).
- the dosage may range from about 0.000001 to about 100 mg I kg body weight / day, once or several times daily, more preferably from about 0.0001 to about 10 mg I kg body weight / day. A range of once or several times a day is preferred. This dose can be appropriately adjusted according to the type of disease, age, weight, and symptoms of the patient.
- compositions are prepared by adding the compound of the present invention to conventional excipients, bulking agents, binders, disintegrants, pH regulators, dissolving agents, etc., and using conventional formulation techniques to produce tablets and pills. , Capsules, granules, powders, solutions, emulsions, suspensions, injections and the like.
- Excipients and bulking agents include, for example, lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, acacia, olive oil, sesame oil, liquor opater, ethylenedalicol, and others commonly used Can be raised.
- an antioxidant such as tocopherol
- the preparation can be encapsulated with an inclusion agent such as cyclodextrin, or the preparation can be encapsulated with a film such as gelatin.
- the compound can be prepared as an OZW-type emulsion preparation (emulsion) using a phospholipid or a nonionic surfactant as an emulsifier as described in JP-A-6-298642.
- the emulsifiers can be used alone or in combination of two or more. The addition amount may be appropriately determined, but is preferably 0.01 to 10% (W / V), preferably 0.01 to 5% (W / V). It is.
- the phospholipids soybean-derived phospholipids, egg yolk-derived phospholipids, lysolecithin, phosphatidylcholine (lecithin), phosphatidylserine and the like can be used alone or in combination.
- non-surfactant examples include a polyoxyethylene-polyoxypropylene block copolymer having a molecular weight of 500 to 1500 (for example, Pluronic F-68), a molecular weight of 100 to 100; Polyalkylene glycol having a molecular weight of 100, a polyoxyalkylene copolymer having a molecular weight of 100 to 200, a hydrogenated castor oil polyoxyalkylene derivative, a castor oil polyoxyalkylene derivative, and glycerin.
- Pluronic F-68 Pluronic F-68
- a fatty acid ester, a polyglycerin fatty acid ester, a sorbitan fatty acid ester, a polyoxyethylene castor oil, a hydrogenated castor oil, a polyoxyethylene alkyl ether, a sucrose fatty acid ester and the like are preferably used alone or in combination, but are not limited thereto.
- the compound of the present invention can be produced as follows.
- R is an alkyl group having 1 to 10 carbon atoms which may be linear or branched.
- R A is hydrogen or an alkyl group having 1 to 10 carbon atoms which may be linear or branched.
- Formula VIII compound A—C ⁇ 2 —R, [R, is hydrogen or carbon number :! Represents an alkyl group of from 4 to 4, wherein A is an optionally substituted CH 3 C n CH ( 2n—2 () — (n is any integer between 4 and 22; Which represents a saturation number and represents a force between 0 and 7 and an integer)] as a starting material.
- the amine of formula VI as a starting material can be synthesized according to a conventional method.
- the starting carboxylic acid or ester of the formula VIII can be synthesized according to a conventional method.
- an ester it can be produced from the corresponding carboxylic acid or a salt thereof by a usual ester forming reaction.
- the corresponding carboxylic acid or The salt can be synthetic or natural. Synthetic products are better in terms of economy, but natural products are preferable because they have less toxicity. Natural products include, for example, those separated and purified from fish and the like.
- the method of introducing a substituent in the synthesis includes a method commonly used by those skilled in the art, for example, a method of introducing a substituent into a carboxylic acid or esterol of the formula VIII by a substitution or addition reaction.
- the substituent is an alkyl group
- CH 3 C n H - it can be introduced with an alkylating agent (2 n 2m) CO OH.
- the substituent when it is an 0H group, it may be synthesized by hydroxylating naturally occurring DHA and fractionating it by HPLC or the like, and there is no particular limitation.
- 10-200 mM DHA is added as a substrate to a suspension of cell lines derived from human leukocytes such as rainbow trout gill cells, epithelial cells, mammalian platelets, or RBL-1 at 1 to 50 ° C at 10 to 37 ° C. It can also be obtained by reacting for a minute.
- each 0H derivative was extracted using an organic solvent (chloroform, methanol, ethyl acetate, acetonitrile, etc.). It can be fractionated by HPLC or thin-layer chromatography using a developing solvent (e.g., chloroform, methanol, ethyl acetate, acetonitrile, water, trifluoroacetic acid, etc.), but not limited to these methods. Absent. Also, each 0H derivative can be prepared by a selective synthesis method using a site-specific enzyme. 4-OH-DHA ⁇ 10-0H-DHA, 11-OH-DHA, 14-OH-DHA, 8-OH-DHA, and 17-OH-DHA (S-isomer) It is marketed by industry and can be obtained.
- an organic solvent chloroform, methanol, ethyl acetate, acetonitrile, etc.
- a developing solvent e.g., chloroform, methanol, ethyl
- the amine of formula VI or the phenolic acid or esternole of formula VIII may be separated or used as dissolved in a solvent.
- amidation method is not limited, it can be generally synthesized by a mixed acid anhydride method.
- the following method is given.
- the compounds of the present invention can be prepared by reacting a reactant of an amine of formula VI with a trialkylaluminum, especially (CH 3 ) 3 A1, with an ester of formula VI II.
- a reactant of an amine of formula VI with a trialkylaluminum, especially (CH 3 ) 3 A1, with an ester of formula VI II.
- the reaction is illustrated in detail using the following scheme (for convenience, where the ester of Formula VIII is not substituted with a substituent).
- the formation reaction of the VII compound in the first step is carried out by reacting an amine of the formula VI (preferably an acid addition salt such as a hydrochloric acid salt) with (CH 3 ) 3 A1.
- This reaction is preferably performed in an aromatic hydrocarbon solvent (eg, toluene, xylene, benzene) under cooling.
- (CH 3 ) 3 A1 is preferably 0.5 to 5.0 equivalents to 1 equivalent of the VI compound.
- the second step is carried out by reacting the VIII conjugate obtained in the first step with an ester of the formula VIIII.
- This reaction is preferably performed in an aromatic hydrocarbon solvent (eg, toluene, xylene, benzene) under heating.
- the reaction temperature is 40-70. C is preferred.
- the reaction temperature preferably does not exceed about 70 ° C., as the product is liable to decompose.
- the reaction time is preferably 1 to 5 hours.
- ester of the formula VIII I is 0.5 to 5 equivalents to 1 equivalent of the VII compound.
- a carboxylic acid of formula VI II A—CO—OH [A is an optionally substituted CH 3 C n H ( 2n ⁇ 2m ) — (n is any integer between 4 and 22, and m is Represents an unsaturated number, and is an integer between 0 and 7).
- the compound of the present invention can also be obtained by reacting
- Step 1 above The reaction to form an acid chloride by the reaction of the carboxylic acid of formula VIII with (COC 1) 2 is performed in an aromatic hydrocarbon solvent (eg, toluene, xylene, benzene) under cooling. Is preferred. At this time, for one equivalent of the carboxylic acid of the formula VIII: A—CO—OH, (COC 1) 2 is: It is preferably from 5 to 5 equivalents.
- an aromatic hydrocarbon solvent eg, toluene, xylene, benzene
- Second step The reaction between the acid chloride obtained in the first step and the amine of the formula VI is carried out in a chlorocarbon solvent (for example, dichloromethane, chloroform) or an aromatic carbon solvent. (Eg, toluene, xylene, benzene).
- the reaction temperature is preferably 15 to + 5 ° C.
- the reaction temperature does not exceed about + 5 ° C, as the product is prone to decomposition.
- the reaction time is preferably 0.5 to 5 hours.
- the amount of the amine of the formula VI is preferably 1 to 5 equivalents relative to 1 equivalent of the acid chloride.
- the compound of the present invention can be isolated and purified according to a conventional method (filtration, solvent extraction, recrystallization, reprecipitation, chromatography, or the like), if necessary.
- the stereoisomer can be a stereochemically pure isomer by selecting an appropriate raw material or, in the case of a mixture of stereoisomers, by chromatography or racemic resolution.
- Example 1 Synthesis of (4Z, 7Z, 10Z, 13Z, 16Z, 19Z) — N _ (4-methylbiperazine-1 1 —inole) docosahexaconamide (Compound 1)
- 0.84 ml of a 15% Me 3 Al solution in n-hexane is mixed with 1.34 ml of toluene dried using MS 4A, and cooled in an ice-methanol bath while cooling 2- (3-aminopropyl) 1-1 in 0.6 ml of toluene.
- 2-(2-aminopropyl) 1-1 in 0.6 ml of toluene.
- -0.167 g of methylpyrrolidine was added dropwise over about 1 minute (internal temperature-15 ° C). After stirring for 20 minutes, the temperature was raised to 20 ° C., and 0.6 ml of toluene of 0.42 g (1.2 mmol) of DHA ethyl ester was added dropwise (internal temperature: 20 ° C.).
- Ph 3 P (5.04 g, 19.2 mmol) was added to a solution of the above mixture (2.48 g) in CH 3 CN (60 ml), and then CBr 4 (6.37 g, 19.2 mmol) in CH 3 CN (15 ml) was added under ice cooling. The solution was added dropwise, followed by stirring at room temperature for 15 hours. The reaction liquid was condensed under reduced pressure, the residue was purified on silica gel force column chromatography (Si0 2 150 g, AcOEt) to (5 ⁇ -5- (Puromomechinore) - 1 - methylpyrrolidin - 2-one (2.68 g, 98 , 5%).
- Raney- ⁇ (1.5 ml) was added to a solution of 2-((2v3 ⁇ 4-1-methinole-5-thioxopyrrolidine-2-yl) ethanenitrile (1.36 g, 8.8 mmol) in EtOH (30 ml) and added for 24 hours.
- the mixture was heated to reflux (the raw material did not completely disappear by TLC), the inorganic matter was removed by filtration, the solvent was distilled off under reduced pressure, and the residue was removed.
- Compound 2-MS An OZW emulsion preparation of Compound 2 (Compound 2-MS) was prepared as follows. 6.0 g of purified egg yolk lecithin and 50.0 mg of compound 2 were added to 50.0 g of purified soybean oil, and dissolved by heating at 40 to 45 ° C. After adding 11.5 mg of glycerin to the Japanese Pharmacopoeia, the total amount was made up to 500 ml with distilled water for injection, and the mixture was subjected to coarse milking using a homomixer. This was passed five times using a Menton-Gaulin type homogenizer under a pressure of 600 kg / cm 2 to perform fine emulsification. This resulted in a very fine, homogenized compound 2-MS formulation.
- Physiological saline was used as a negative control.
- the aggregation inhibition curve is shown in FIG.
- IC 5 the 50% P stopping point for platelet aggregation. are shown in Table 1 below.
- n of C n H ( 2n- 1m ) is any integer between 6 and 20, and the number of unsaturations m is any one between 0 and 6. It was confirmed that the platelet with an integer of ⁇ ⁇ ⁇ had a platelet aggregation inhibitory action. In vitro platelet aggregation by various inducers.
- the preparation of the aggregation inducer was performed as follows.
- Collagen and ADP were purchased from MCM and used according to the attached preparation method.
- Serotonin, epinephrine, and thrombin were purchased from Sigma and dissolved in saline for injection (Otsuka Pharmaceutical Factory).
- Arachidonic acid was purchased from Cayman and dispersed in saline for injection (Otsuka Pharmaceutical Factory) using a throw-in type ultrasonic oscillator (Nippon Seiki US150, tip tip ⁇ 3.5 thigh).
- U46619 simulated tropoxane was purchased from Funakoshi Co., Ltd. and dissolved in saline for injection (Otsuka Pharmaceutical Factory).
- Collagen (0.1 to: 1 ⁇ g Zm 1), arachidonic acid (l mM), ADP (1 x M), thrombin (1 U / m 1), serotonin (100 / M), epinephrine (100 0-200 ⁇ M) and U46661 (3 ⁇ ⁇ ) were used.
- Compound 2 was used as a test drug.
- indomethacin was used, and the inhibition of platelet aggregation induced by collagen was measured.
- Blood was collected from each of the forearm veins of the volunteers using an 18G needle at a rate of 10 ml per person. Blood was gently dropped into a 15. ml Falcon tube containing 1 ml of 3.8% sodium taenoate (Yamanouchi Pharmaceutical, Chitral), and the lid was closed. After that, the blood was centrifuged at room temperature for 10 minutes at 900 rpm, and the supernatant (multiple platelet fraction, platelet rich plasma, PRP) was collected. The residue was further centrifuged at 2,500 rpm for 15 minutes to obtain a supernatant (platelet poor fraction, platelet poor plasma, PPP). The platelet density of PRP was measured with a hemocytometer (Sysmec Corporation) and diluted with PPP to adjust the platelet density to 300,000 / 1.
- a hemocytometer Sysmec Corporation
- the preparation of the aggregation inducer was performed in the same manner as described above.
- the dose of the inducer was determined for each experiment.
- the concentration of the inducer was set for each experiment.
- alpha-granules (PDGF, serotonin, ADP, etc.) released from activated platelets are triggered following primary aggregation, and secondary aggregation occurs again. proceed. This time, ADP or Epinephrine The effect of the test substance on the secondary agglutination due to is also investigated.
- Serotonin alone is unlikely to cause platelet aggregation. Therefore, a combination of serotonin + collagen or serotonin + ADP was used as an inducing substance.
- the doses were determined for each experiment with doses that did not induce aggregation of each substance alone, and doses that did not induce aggregation were set and used in combination. For example, if serotonin alone causes 1 mM but hardly causes 0.5 mM, whereas ADP alone causes 0.25 mM but not 0.11 ⁇ , serotonin 0.25 mM + ADP 0.05 mM was set.
- test substance was Compound 2, and the preparation was performed in the same manner as described above.
- the transmittance was measured in the same manner as described above.
- SD male rats (SPF, 8 weeks old) Administer 1 Omg / kg of compound 2 to the tail vein, collect blood at 10 minutes, 30 minutes, and 1 hour after administration, and collect the prepared platelets. Using this, the aggregation rate when platelet aggregation was induced with 0.3 to 6 ⁇ g / ml of collagen was examined. As a control group, the agglutination rate of those to which a solvent (physiological saline) was administered was measured. Preparation of platelets and measurement of the aggregation rate were performed in the same manner as in Test Example 1.
- Platelet aggregation was suppressed at 10 minutes, 30 minutes and 1 hour after administration of Compound 2 compared with the vehicle administration group, but the effect was observed at 10 minutes or 30 minutes after administration. 1 hour after intravenous administration, platelet aggregation was more strongly suppressed. Therefore, the measurement points in the following experiments were set one hour later.
- Rats were dosed with 1, 0.1, 0.01, 0.003, 0.001, 0.0003, or 0.0001 mg / kg of Compound 2 in the tail vein. Blood was collected 60 minutes later, and platelet aggregation was induced with 4-7 ⁇ g / ml collagen using the prepared platelets. Preparation of platelets and measurement of the aggregation rate were performed in the same manner as in Test Example 1.
- Platelet aggregation was suppressed in the compound 2 administration group at 1, 0.1, 0.011, or 0.001 mg / kg as compared with the vehicle administration group. In the group administered with 0.0001 mg I kg, platelet aggregation was suppressed in the induction of collagen at a low concentration of 4 ⁇ g / ml, although platelet aggregation was suppressed as compared with the group administered with the solvent.
- Fig. 4 shows the results.
- Compound 5 was also found to inhibit platelet aggregation.
- the effect of ex vivo inhibition of platelet aggregation shown in this example is compared with that of in vitro.
- IC 5 obtained in ex vivo experiments.
- a value of 630 ng / kg can be inferred to be the dose at which the blood concentration of compound 2 reaches 26 nM, if the rat blood volume is estimated to be approximately 60 ml I kg.
- This value is IC 5 in vitro. It is more dilute than the value of 2, 1 ⁇ 0.8 ⁇ M, which means a low concentration of about 1/80.
- the action of ex vivo inhibition of platelet aggregation is not limited to simply inhibiting platelet aggregation by the compound of the present invention, for example, suppressing the interaction between neutrophils and platelets involved in platelet aggregation.
- the compound of the present invention is metabolized, and the metabolite exerts an effect on platelets while platelet aggregation is strongly suppressed in the body.
- a single oral dose of 10, 2 or 0.1 mg / kg of compound 2 was given to rats using a probe.
- a solvent physiological saline
- the survival rate of the compound 2 administration group was 7/10
- the compound 2 showed a higher survival rate than the solvent group.
- a rat rat phosphate-induced peripheral circulatory disorder model which is widely used as a peripheral circulatory disorder model, was used.
- the single dose of Compound 2 was set to 10 ⁇ g / kg, 30 ⁇ g / kg or 100 ⁇ g / kg, and it was examined whether dose necrosis was improved in a dose-dependent manner.
- a vehicle physiological saline
- the test was performed in the same manner as in (1) above. However, administration of Compound 2 was started 1 hour before lauric acid treatment, then administered 6 hours after lauric acid administration, and repeated once a day for 14 days. As a control, a solvent (physiological saline) was similarly administered.
- Figure 7 shows the results. It was shown that Dangidou 2 improved the leg death score in a dose-dependent manner.
- Example 14 the compound 2-MS prepared in Example 14 (single dose: 100 / g / kg as active ingredient) was used, and Palux (registered trademark) (Lipo PG El, Taisho) was used as a positive control.
- Palux registered trademark
- Lipo PG El, Taisho a positive control.
- Pseudovascular in vitro inflammation model was performed according to the method described in Biopharmaceutical Science Laboratory Course, 12 Inflammation and Allergic Diseases, li p. 327-341 (edited by Kazuo Oozaki, Hirokawa Shoten, published May 15, 1993). Created.
- transwell manufactured by Krabo
- a transwell manufactured by Krabo
- a porous polycarbonate membrane with a pore size of 3 ⁇ m
- one layer of calcium endothelial cells was attached to the bottom of the membrane, and the temperature was adjusted to 37 ° C. 5% C0 2 under the conditions, and incubated for 80 minutes.
- a fluorescently labeled neutrophil suspension is added to the upper chamber of the transfer well, and at the same time, TN Fa is added to the cell suspension in the upper chamber to a final concentration of 50, 25 or 17 ng / ml. Suspended.
- neutrophils penetrating from the upper chamber through the vascular endothelial cell layer and penetrating to the lower chamber, and adhering to the endothelial cell layer are favorable in response to TNFo! It mimics the movement of neutrophils from blood vessels to inflamed sites.
- Both Compound 1 and Compound 2 inhibited neutrophil penetration in a concentration-dependent manner.
- both Compound 1 and Compound 2 act to suppress the interaction between neutrophils and vascular endothelial cells, and may act in the direction of anti-inflammatory. Since Compound 1 or 2 acts anti-inflammatory, it is considered that Compound 1 or 2 may maintain the circulatory organ homeostasis and act in the direction of improving the disease state.
- Rats were intravenously injected with Rose Bengal dye (20 mg / kg), and the middle cerebral artery was irradiated with green laser light (wavelength 540 nm) for 10 minutes to induce arterial occlusion by reactive oxygen species.
- Compound 2 was intravenously administered after the end of laser light irradiation.
- the dose of Yidani Compound 2 was 1 mg / kg, and it was examined whether cerebral infarction was improved.
- a solvent physiological saline
- Transected sections (1 thigh thickness) of the excised brain were prepared and immersed in trifenyltetrazolium, and the living tissues were stained red. Since the infarcted area became white and could be clearly distinguished from the living tissue, the infarcted area was measured, and the infarcted area ratio (the ratio of the infarcted area to the cross section of the brain) was used for evaluation.
- a rat carotid intimal hyperplasia model which is widely used as a restenosis model after PTCA, was used.
- the tip of a balloon catheter (Fogty catheter 2 Fr, Butterstar) was inserted from the rat large J9 retreated artery and guided to the carotid artery. Air (0.3 mL) was injected into the balloon, and the balloon was inflated. With the balloon inflated, the Nolan catheter was withdrawn to the aortic arch and the carotid intima was injured three times.
- the OZW-type emulsion (Compound 2-MS) of compound 2 prepared in Example 14 was administered intravenously once a day, and 2 weeks after the intimal injury. Repeated intravenous administration once a day.
- the single dose of Compound 2-MS was set to 100 // g I kg or 300 y g I kg (each as an active ingredient), and the ability to suppress intimal hyperplasia in a dose-dependent manner was examined.
- a negative control a compound containing no! /! OZW emulsion was administered.
- enalapril Sigma was used as a positive control, and 30 mg / kg was orally administered once a day in the same manner as described above.
- Intimal thickening was assessed 2 weeks after injury. Hematoxylin-Eosin (HE) staining was performed on the excised cross section of the carotid artery, and the vascular lumen area, the area surrounded by the inner elastic plate, and the area surrounded by the outer elastic plate were measured. Neointimal area (area surrounded by inner elastic plate-area of blood vessel lumen) Intima using ratio to media area (area surrounded by outer elastic plate-area surrounded by inner elastic plate) Thickening was evaluated.
- HE Hematoxylin-Eosin
- test substance The effect of the test substance on vascular smooth muscle cell proliferation was examined.
- vascular smooth muscle cells With the progression of atherosclerosis, vascular smooth muscle cells are transformed from contractile to synthetic, and vascular smooth muscle cells proliferate while secreting inflammatory cytokines such as PDGF. (Loss's hypothesis).
- Vascular smooth muscle cells prepared by the Explant culture method were cultured in a DMEM medium (Gibco) containing 10% fetal calf serum, subcultured several times and stabilized, and then 5 ⁇ 10 3 cells / cm 2 The cells were seeded at a cell density of 5% and used for the experiment.
- Compound 2 was added to the above cells in combination with 50 ng / ml of growth factor PDGF (Sigma), and 24 hours later, BrdU Atssei (Science '82, 218, p. 474, Cytometry, 85, 6, p. 584) The cell density was measured by As a control, the cell density was measured when no drug was added.
- Relative smooth muscle cell number% [cell number in experimental group] I [cell number in control] x 100
- the compounds of the present invention can strongly inhibit platelet aggregation (particularly, platelet aggregation induced by collagen), can suppress inflammation, and can prevent cardiovascular diseases (eg, thrombotic diseases, arteriosclerosis). Disease or hyperlipidemic disease).
- platelet aggregation particularly, platelet aggregation induced by collagen
- cardiovascular diseases eg, thrombotic diseases, arteriosclerosis. Disease or hyperlipidemic disease.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/481,062 US6949553B2 (en) | 2001-06-18 | 2002-06-18 | Aliphatic compounds, their synthesis method, and utilization of the same |
CA002450856A CA2450856A1 (en) | 2001-06-18 | 2002-06-18 | Novel aliphatic compounds, their synthesis method, and utilization method of the same |
EP02738748A EP1408030B1 (en) | 2001-06-18 | 2002-06-18 | Novel aliphatic compound, method of synthesis, and method of utilization |
DE60208554T DE60208554T2 (de) | 2001-06-18 | 2002-06-18 | Neue aliphatische verbindung, syntheseverfahren und anwendungsverfahren |
JP2003505313A JP4303103B2 (ja) | 2001-06-18 | 2002-06-18 | 新規脂肪族化合物、合成方法、利用方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001183384 | 2001-06-18 | ||
JP2001-183384 | 2001-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002102770A1 true WO2002102770A1 (fr) | 2002-12-27 |
Family
ID=19023341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006067 WO2002102770A1 (fr) | 2001-06-18 | 2002-06-18 | Nouveau compose aliphatique, technique de synthese et technique d'utilisation |
Country Status (7)
Country | Link |
---|---|
US (1) | US6949553B2 (ja) |
EP (1) | EP1408030B1 (ja) |
JP (1) | JP4303103B2 (ja) |
AT (1) | ATE315024T1 (ja) |
CA (1) | CA2450856A1 (ja) |
DE (1) | DE60208554T2 (ja) |
WO (1) | WO2002102770A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013521309A (ja) * | 2010-03-05 | 2013-06-10 | サノフイ | 2−(シクロヘキシルメチル)−n−{2−[(2s)−1−メチルピロリジン−2−イル]エチル}−1,2,3,4−テトラヒドロイソキノリン−7−スルホンアミドの製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002102364A1 (ja) * | 2001-06-18 | 2004-09-30 | 山田 幸子 | PPARγ作動性医薬組成物 |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3284177A (en) * | 1963-06-19 | 1966-11-08 | Chevron Res | Gasoline composition |
JPS50120485A (ja) * | 1974-03-08 | 1975-09-20 | ||
JPS52131507A (en) * | 1976-04-24 | 1977-11-04 | Sankyo Co Ltd | Polyprenyl derivatives |
JPS5728037A (en) * | 1980-07-29 | 1982-02-15 | Nippon Shinyaku Co Ltd | Octadecenoic acid amide |
JPS60123451A (ja) * | 1983-12-07 | 1985-07-02 | Eisai Co Ltd | ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2425923A1 (en) | 2000-10-12 | 2003-04-11 | Maruha Corporation | Novel aliphatic compounds, process for their preparation and their usage |
-
2002
- 2002-06-18 CA CA002450856A patent/CA2450856A1/en not_active Abandoned
- 2002-06-18 DE DE60208554T patent/DE60208554T2/de not_active Expired - Fee Related
- 2002-06-18 WO PCT/JP2002/006067 patent/WO2002102770A1/ja active IP Right Grant
- 2002-06-18 JP JP2003505313A patent/JP4303103B2/ja not_active Expired - Fee Related
- 2002-06-18 EP EP02738748A patent/EP1408030B1/en not_active Expired - Lifetime
- 2002-06-18 US US10/481,062 patent/US6949553B2/en not_active Expired - Fee Related
- 2002-06-18 AT AT02738748T patent/ATE315024T1/de not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3284177A (en) * | 1963-06-19 | 1966-11-08 | Chevron Res | Gasoline composition |
JPS50120485A (ja) * | 1974-03-08 | 1975-09-20 | ||
JPS52131507A (en) * | 1976-04-24 | 1977-11-04 | Sankyo Co Ltd | Polyprenyl derivatives |
JPS5728037A (en) * | 1980-07-29 | 1982-02-15 | Nippon Shinyaku Co Ltd | Octadecenoic acid amide |
JPS60123451A (ja) * | 1983-12-07 | 1985-07-02 | Eisai Co Ltd | ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬 |
Non-Patent Citations (1)
Title |
---|
WANG DAXI, WANG ZHAOHUI: "Experimental studies of structure and inhibition effciency of imidazoline derivatives", ZHONG GUO FUSHI YU FANGHU XUEBAO, vol. 21, no. 2, 2001, pages 112 - 116, XP002955099 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013521309A (ja) * | 2010-03-05 | 2013-06-10 | サノフイ | 2−(シクロヘキシルメチル)−n−{2−[(2s)−1−メチルピロリジン−2−イル]エチル}−1,2,3,4−テトラヒドロイソキノリン−7−スルホンアミドの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
DE60208554D1 (de) | 2006-03-30 |
EP1408030A1 (en) | 2004-04-14 |
ATE315024T1 (de) | 2006-02-15 |
CA2450856A1 (en) | 2002-12-27 |
US6949553B2 (en) | 2005-09-27 |
EP1408030B1 (en) | 2006-01-04 |
JP4303103B2 (ja) | 2009-07-29 |
EP1408030A4 (en) | 2004-09-08 |
US20040162435A1 (en) | 2004-08-19 |
DE60208554T2 (de) | 2006-11-09 |
JPWO2002102770A1 (ja) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2569063C2 (ru) | Конъюгаты жирных кислот и ниацина и их применение | |
TWI433830B (zh) | 胺基羧酸衍生物及其醫藥用途 | |
US6159964A (en) | Vitronectin receptor antagonists | |
RU2446801C2 (ru) | Применение соединений формулы а-r-x или их фармацевтически приемлемых солей для получения фармацевтической композиции | |
WO2005020882A2 (ja) | S1p受容体結合能を有する化合物およびその医薬用途 | |
JP5568484B2 (ja) | Lpa受容体アゴニストおよびアンタゴニスト | |
JP2000319277A (ja) | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 | |
JP2000502708A (ja) | ビトロネクチン受容体拮抗物質 | |
JP3553966B2 (ja) | 非−β−酸化可能脂肪酸類似体、治療用活性薬剤としてのその利用及びその調製方法 | |
AU2021319847A1 (en) | Low molecular weight protein degraders and their applications | |
KR20150130398A (ko) | 비시클로 [2.2.2] 산 gpr120 조절제 | |
KR20150128860A (ko) | 옥사비시클로 [2.2.2] 산 gpr120 조절제 | |
JP2930245B2 (ja) | 1,2,3,4―テトラヒドロ―9―アクリジナミンの誘導体 | |
JP4035759B2 (ja) | アミノアルコールリン酸化合物、製造方法、及びその利用方法 | |
EP2205072A1 (en) | Methods for treating a variety of diseases and conditions, and compounds useful therefor | |
JPWO2008139879A1 (ja) | G蛋白質共役型レセプター抑制剤および医薬 | |
JP6615207B2 (ja) | 複素環式化合物及びその使用 | |
JP4099226B2 (ja) | 哺乳類細胞の増殖を治療するためのハロゲン化芳香族の使用 | |
EP3191453A1 (en) | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators | |
JP2000319278A (ja) | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 | |
JP4303103B2 (ja) | 新規脂肪族化合物、合成方法、利用方法 | |
JPWO2003101983A1 (ja) | テトラヒドロピラン誘導体 | |
JPH05194524A (ja) | 血栓症および血管痙攣症の治療に有用な7−オキサビシクロヘプチル置換複素環式アミドプロスタグランジン類縁体 | |
EP4219458A2 (en) | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | |
JP2021505537A (ja) | クレアチンプロドラッグ、組成物及びその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10481062 Country of ref document: US Ref document number: 2450856 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003505313 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002738748 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738748 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002738748 Country of ref document: EP |